| HEBUTERNE, Xavier |
ACTIVE, NCT02425852: A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis |
|
|
| Completed | 4 | 65 | Europe | Azathioprine, Infliximab, Prednisolone, Hydrocortisone | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Ulcerative Colitis | 06/22 | 01/23 | | |
| Active, not recruiting | 4 | 33 | Europe | Ustekinumab, Stelara, Placebo | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Janssen, LP | Crohn's Disease | 06/25 | 12/25 | | |
| Active, not recruiting | 4 | 150 | Europe | Infliximab, Infliximab injection, Vedolizumab Injection, Vedolizumab | Rennes University Hospital | Ulcerative Colitis | 12/24 | 05/25 | | |
VEDIAN, NCT06180382: Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. |
|
|
| Recruiting | 4 | 220 | Europe | Adalimumab, Vedolizumab | Centre Hospitalier Universitaire de Saint Etienne, Takeda France | Crohn's Disease | 01/26 | 01/27 | | |
NCT04183608 / 2018-003490-10: A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab |
|
|
| Recruiting | 4 | 238 | Europe | Adalimumab, Calprotectin, e-Monitoring, Therapy Education | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, AbbVie | Ulcerative Colitis | 04/25 | 05/28 | | |
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
CYTOVEDO, NCT04064697: Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy |
|
|
| Terminated | 3 | 6 | Europe | Valganciclovir, antiviral therapy | Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France | Ulcerative Colitis, Unspecified | 11/23 | 02/24 | | |
| Recruiting | 3 | 612 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 08/24 | 09/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
| Terminated | N/A | 67 | Europe | Blood sample, Rectosigmoidoscopy | Centre Hospitalier Universitaire de Saint Etienne, Takeda, Theradiag | Ulcerative Colitis | 04/22 | 06/22 | | |
| Recruiting | N/A | 575 | Europe | bio-banking collection | Saint-Louis Hospital, Paris, France | Crohn Disease | 12/25 | 12/26 | | |
Deeper, NCT04973423: STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL CALPROTECTIN FOLLOW-UP |
|
|
| Recruiting | N/A | 180 | Europe | MRI | University Hospital, Clermont-Ferrand | Crohn Disease, Calprotectin, MRI | 03/27 | 08/27 | | |
| Gogia, Sudhanshu |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 08/24 | 09/25 | | |
